Evogene Ltd. (EVGN)
Evogene Statistics
Share Statistics
Evogene has 6.67M shares outstanding. The number of shares has increased by -89.39% in one year.
| Shares Outstanding | 6.67M |
| Shares Change (YoY) | -89.39% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | 7.75% |
| Shares Floating | 6.57M |
| Failed to Deliver (FTD) Shares | 445 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 25.52K, so 0.48% of the outstanding shares have been sold short.
| Short Interest | 25.52K |
| Short % of Shares Out | 0.48% |
| Short % of Float | 0.48% |
| Short Ratio (days to cover) | 1.05 |
Valuation Ratios
The PE ratio is -0.65 and the forward PE ratio is -0.84. Evogene's PEG ratio is 0.01.
| PE Ratio | -0.65 |
| Forward PE | -0.84 |
| PS Ratio | 1.25 |
| Forward PS | 0.1 |
| PB Ratio | -7.34 |
| P/FCF Ratio | -0.52 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Evogene.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of -8.87.
| Current Ratio | 1.15 |
| Quick Ratio | 1.06 |
| Debt / Equity | -8.87 |
| Debt / EBITDA | -0.83 |
| Debt / FCF | -0.63 |
| Interest Coverage | -352.54 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $72.74K |
| Profits Per Employee | $-140.9K |
| Employee Count | 117 |
| Asset Turnover | 0.21 |
| Inventory Turnover | 1.47 |
Taxes
| Income Tax | 9K |
| Effective Tax Rate | -0.05% |
Stock Price Statistics
The stock price has increased by -83.57% in the last 52 weeks. The beta is 1.18, so Evogene's price volatility has been higher than the market average.
| Beta | 1.18 |
| 52-Week Price Change | -83.57% |
| 50-Day Moving Average | 1.27 |
| 200-Day Moving Average | 2.27 |
| Relative Strength Index (RSI) | 48.33 |
| Average Volume (20 Days) | 377.26K |
Income Statement
In the last 12 months, Evogene had revenue of 8.51M and earned -16.48M in profits. Earnings per share was -2.89.
| Revenue | 8.51M |
| Gross Profit | 5.83M |
| Operating Income | -22.21M |
| Net Income | -16.48M |
| EBITDA | -15.48M |
| EBIT | -17.98M |
| Earnings Per Share (EPS) | -2.89 |
Balance Sheet
The company has 15.3M in cash and 12.87M in debt, giving a net cash position of 2.43M.
| Cash & Cash Equivalents | 15.3M |
| Total Debt | 12.87M |
| Net Cash | 2.43M |
| Retained Earnings | -274.07M |
| Total Assets | 39.86M |
| Working Capital | 2.89M |
Cash Flow
In the last 12 months, operating cash flow was -19.7M and capital expenditures -626K, giving a free cash flow of -20.33M.
| Operating Cash Flow | -19.7M |
| Capital Expenditures | -626K |
| Free Cash Flow | -20.33M |
| FCF Per Share | -3.57 |
Margins
Gross margin is 68.48%, with operating and profit margins of -260.96% and -193.69%.
| Gross Margin | 68.48% |
| Operating Margin | -260.96% |
| Pretax Margin | -212.02% |
| Profit Margin | -193.69% |
| EBITDA Margin | -181.86% |
| EBIT Margin | -260.96% |
| FCF Margin | -238.82% |
Dividends & Yields
EVGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for EVGN is $12, which is 934.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $12 |
| Price Target Difference | 934.5% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 25, 2024. It was a backward split with a ratio of 1:10.
| Last Split Date | Jul 25, 2024 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -10.63 |
| Piotroski F-Score | 3 |